Business
Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, jointly announced with Sanegene Bio USA Inc. (SanegeneBio), a global clinical-stage biotechnology company focused on developing best-in-class RNAi medicines for obesity, cardiometabolic, and autoimmune diseases, that the preli
About this update from Innovent Biologics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration.","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"The clinical Phase 1 data of IBI3016 further support the potential for biannual subcutaneous dosing for the treatment of hypertension. Next-step development is scheduled to initiate soon.","length":187,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":351,"olType":false},{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Nov. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, jointly announced with Sanegene Bio USA Inc. (SanegeneBio), a global clinical-stage biotechnology company focused on developing best-in-class RNAi medicines for obesity, cardiometabolic, and autoimmune diseases, that the preliminary results from the first-in-human (FIH) Phase 1 clinical study of IBI3016 (SanegeneBio's R&D code: SGB-3908), an experimental small interfering RNA (siRNA) medicine targeting angiotensinogen mRNA (AGT), were reported at the 2025 American Heart Association (AHA) scientific sessions. Dr. Fangfang Wang from Peking University Third Hospital, delivered the moderated digital poster presentation of the study results.","length":993,"tagName":"p"},{"type":"text","content":"This FIH study (NCT06501586/CTR20242500) is a randomized, double-blind, placebo-controlled, single-ascending-dose trial in healthy subjects and patients with mild hypertension to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously administered IBI3016.","length":302,"tagName":"p"},{"type":"text","content":"As of July 1, 2025, 40 healthy subjects and mild hypertensive subjects were enrolled and randomized into 5 cohorts (each cohort had a 6:2 ratio of IBI3016 dose group to placebo group). All subjects were Chinese, with a median age (range) of 37 years (24-54 years), 30% female, mean BMI of 25.2 kg/m², and baseline 24-hour ambulatory blood pressure (BP) mean of 122/74 mmHg. There were no sig...